Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | FNTA | P49354 | 5/20 | 0.55 |
| ▸ | FNTB | P49356 | 5/20 | 0.55 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13160969 | 0.84 | CYP11B1 (0.50) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL3463864 | 0.82 | FNTA (0.47) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL1097299 | 0.79 | CYP19A1 (0.42) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL8812553 | 0.77 | CYP2A6 (0.46) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL6366103 | 0.77 | CYP11B1 (0.79) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL7083825 | 0.76 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| Bromide SCHEMBL3625451 | 0.76 | CYP11B1 (0.77) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL6598797 | 0.76 | FNTA (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL8677989 | 0.76 | CYP11B1 (0.70) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL7507201 | 0.75 | CYP11B1 (0.74) | CYP11B1CYP11B2CYP19A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| US-20040110764-A1 | Inhibitors of prenyl-protein transferase | STUMP CRAIG A (US) | 2004-06-10 | — | — | US | disclosed |
| US-5856326-A | ANTITUMOR, ANTICANCER AGENTS | MERCK & CO., INC. (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | CYP11B1, CYP27A1, CYP17A1 | CYP11B1 1/4885CYP11B2 6/4885CYP19A1 78/4885 |
| US-20040110764-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, PTAR1 | CYP11B1 2149/4885CYP11B2 2804/4885CYP19A1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.